Lilly antibody drug fails in study of hospitalized Covid-19 patients
U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with Covid-19 because it doesnt seem to be helping them.
Independent monitors had paused enrollment in the study two weeks ago because of a possible safety issue. But on Monday, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look did not verify a safety problem but found a low chance that the drug would prove helpful for hospitalized patients.
It is a setback for one of the most promising treatment approaches for Covid-19. President Donald Trump received a similar experimental, two-antibody drug from Regeneron Pharmaceuticals Inc. on an emergency basis when he was sickened with the coronavirus earlier this month.
In a statement Lilly notes that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness. The company also is continuing its own studies testing the drug, which is being developed with the Canadian company AbCellera.
https://www.msn.com/en-us/health/medical/lilly-antibody-drug-fails-in-study-of-hospitalized-covid-19-patients/ar-BB1aricS?li=BBnb7Kz